• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice.所有抗血管生成药物在二线转移性结直肠癌治疗中都一样吗？临床实践专家意见
Front Oncol. 2021 May 10;11:637823. doi: 10.3389/fonc.2021.637823. eCollection 2021.
2
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.抗血管生成药物序贯治疗转移性结直肠癌
Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. Epub 2014 Feb 27.
3
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.阿柏西普治疗转移性结直肠癌的安全性与疗效综述
Expert Opin Drug Saf. 2022 May;21(5):589-597. doi: 10.1080/14740338.2022.2008905. Epub 2022 Jan 5.
4
Targeted therapy for metastatic colorectal cancer: role of aflibercept.转移性结直肠癌的靶向治疗：阿柏西普的作用。
Clin Colorectal Cancer. 2013 Jun;12(2):73-85. doi: 10.1016/j.clcc.2012.08.001. Epub 2012 Oct 24.
5
Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.阿柏西普治疗结直肠癌的药代动力学和药效学评价。
Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):995-1004. doi: 10.1517/17425255.2015.1041920.
6
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Analysis of the VELOUR Trial.贝伐珠单抗治疗史对二线阿柏西普治疗后 VEGF-A 和 PlGF 水平及结局的影响：VELOUR 试验的生物标志物分析。
Clin Cancer Res. 2020 Feb 1;26(3):717-725. doi: 10.1158/1078-0432.CCR-19-1985. Epub 2019 Nov 14.
7
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.EFFORT 研究方案：在不可切除/转移性结直肠癌患者中，FOLFOXIRI 联合贝伐珠单抗治疗进展后或维持治疗期间使用 FOLFIRI 联合阿柏西普二线治疗的前瞻性研究。
BMC Cancer. 2020 Nov 17;20(1):1116. doi: 10.1186/s12885-020-07576-9.
8
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).阿柏西普，二线治疗转移性结直肠癌（mCRC）中靶向血管生成的新方法。
Target Oncol. 2016 Aug;11(4):489-500. doi: 10.1007/s11523-016-0447-4.
9
Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.Ziv-aflibercept：一种新型血管生成抑制剂，用于治疗转移性结直肠癌。
Am J Health Syst Pharm. 2013 Nov 1;70(21):1887-96. doi: 10.2146/ajhp130143.
10
Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.靶向血管生成和肿瘤微环境治疗转移性结直肠癌：阿柏西普的作用。
Gastroenterol Res Pract. 2014;2014:526178. doi: 10.1155/2014/526178. Epub 2014 Jul 21.

引用本文的文献

1
Characterization and validation of a prognostic model for the N6-methyladenosine-associated ferroptosis gene in colon adenocarcinoma.结肠腺癌中N6-甲基腺嘌呤相关铁死亡基因预后模型的特征分析与验证
Transl Cancer Res. 2024 Aug 31;13(8):4389-4407. doi: 10.21037/tcr-24-88. Epub 2024 Aug 6.
2
Multi-Omics analysis elucidates tumor microenvironment and intratumor microbes of angiogenesis subtypes in colon cancer.多组学分析揭示结肠癌血管生成亚型的肿瘤微环境和瘤内微生物。
World J Gastrointest Oncol. 2024 Jul 15;16(7):3169-3192. doi: 10.4251/wjgo.v16.i7.3169.
3
Editorial: Angiogenesis and access to vasculature as a target in gastrointestinal tumors and predictive biomarkers identification: an open challenge.社论：血管生成与作为胃肠道肿瘤靶点的血管通路以及预测性生物标志物的识别：一项公开挑战。
Front Oncol. 2024 May 20;14:1428174. doi: 10.3389/fonc.2024.1428174. eCollection 2024.
4
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging.晚期结直肠癌患者抗血管生成治疗反应的预测：从生物学因素到功能成像
Cancers (Basel). 2024 Mar 30;16(7):1364. doi: 10.3390/cancers16071364.
5
Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges.基于硅藻的纳米医学用于结直肠癌治疗：旧挑战的新方法。
Mar Drugs. 2023 Apr 26;21(5):266. doi: 10.3390/md21050266.
6
Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview.基于免疫检查点抑制剂的结直肠癌联合治疗概述
Int J Gen Med. 2023 Apr 26;16:1527-1540. doi: 10.2147/IJGM.S408349. eCollection 2023.
7
The emerging era of personalized medicine in advanced colorectal cancer.晚期结直肠癌个体化医学的崭新时代。
J Gastroenterol Hepatol. 2022 Aug;37(8):1411-1425. doi: 10.1111/jgh.15937. Epub 2022 Jul 20.
8
Emerging actionable targets to treat therapy-resistant colorectal cancers.治疗难治性结直肠癌的新出现的可操作靶点。
Cancer Drug Resist. 2022 Jan 4;5(1):36-63. doi: 10.20517/cdr.2021.96. eCollection 2022.
9
Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification.液体活检与人工智能作为检测结直肠癌特征的工具：患者分层的现代方法
Front Oncol. 2022 Mar 8;12:856575. doi: 10.3389/fonc.2022.856575. eCollection 2022.
10
Cancer Therapies and Vascular Toxicities.癌症治疗与血管毒性
Curr Treat Options Oncol. 2022 Mar;23(3):333-347. doi: 10.1007/s11864-022-00964-2. Epub 2022 Mar 4.

本文引用的文献

1
Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial.贝伐单抗在转移性结直肠癌一线和二线治疗中的有效性：ITACa随机试验
Ther Adv Med Oncol. 2020 Jul 23;12:1758835920937427. doi: 10.1177/1758835920937427. eCollection 2020.
2
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.动量：一项在胃肠道癌和乳腺癌患者中研究卡培他滨与阿柏西普两种给药方案的I期试验。
Clin Colorectal Cancer. 2020 Dec;19(4):311-318.e1. doi: 10.1016/j.clcc.2020.05.007. Epub 2020 May 29.
3
miR-23a-3p is a Key Regulator of IL-17C-Induced Tumor Angiogenesis in Colorectal Cancer.miR-23a-3p 是白细胞介素 17C 诱导的结直肠癌肿瘤血管生成的关键调节因子。
Cells. 2020 Jun 1;9(6):1363. doi: 10.3390/cells9061363.
4
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy.从“中央”到“血清血管生成中央（CENTRAL）”：抗血管内皮生长因子受体（VEGFR）治疗的循环预测生物标志物
Cancers (Basel). 2020 May 22;12(5):1330. doi: 10.3390/cancers12051330.
5
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.RAS野生型转移性结直肠癌一线抗EGFR治疗后二线抗VEGF治疗的评估：多中心“SLAVE”研究
Cancers (Basel). 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259.
6
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.分子生物学驱动的转移性结直肠癌治疗
Cancers (Basel). 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214.
7
The Role of Anti-Angiogenics in Pre-Treated Metastatic -Mutant Colorectal Cancer: A Pooled Analysis.抗血管生成药物在经预处理的转移性KRAS突变型结直肠癌中的作用：一项汇总分析
Cancers (Basel). 2020 Apr 21;12(4):1022. doi: 10.3390/cancers12041022.
8
Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data.阿柏西普治疗转移性结直肠癌的安全性：基于临床和真实世界数据的文献综述与专家观点
Cancers (Basel). 2020 Mar 31;12(4):844. doi: 10.3390/cancers12040844.
9
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.癌症中抗血管生成疗法的耐药机制
Front Oncol. 2020 Feb 27;10:221. doi: 10.3389/fonc.2020.00221. eCollection 2020.
10
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study.阿柏西普联合氟尿嘧啶、亚叶酸钙和伊立替康（FOLFIRI）在当前临床实践中治疗转移性结直肠癌（mCRC）患者的安全性和有效性：臭氧研究
Cancers (Basel). 2020 Mar 11;12(3):657. doi: 10.3390/cancers12030657.

所有抗血管生成药物在二线转移性结直肠癌治疗中都一样吗？临床实践专家意见

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice.

作者信息

Lai Eleonora, Cascinu Stefano, Scartozzi Mario

机构信息

Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy.

Oncologia Medica, Università Vita-Salute, IRCCS Ospedale San Raffaele, Milano, Italy.

出版信息

Front Oncol. 2021 May 10;11:637823. doi: 10.3389/fonc.2021.637823. eCollection 2021.

DOI:10.3389/fonc.2021.637823
PMID:34041019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8141840/
Abstract

Targeting tumor-driven angiogenesis is an effective strategy in the management of metastatic colorectal cancer (mCRC); however, the choice of second-line therapy is complicated by the availability of several drugs, the occurrence of resistance and the lack of validated prognostic and predictive biomarkers. This review examines the use of angiogenesis-targeted therapies for the second-line management of mCRC patients. Mechanisms of resistance and anti-placental growth factor agents are discussed, and the role of aflibercept, a recombinant fusion protein consisting of portions of human vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2, is highlighted. The novel mechanism of action of aflibercept makes it a useful second-line agent in mCRC patients progressing after oxaliplatin-based chemotherapy, as well as in those with resistance after bevacizumab.

摘要

靶向肿瘤驱动的血管生成是转移性结直肠癌（mCRC）治疗中的一种有效策略；然而，二线治疗的选择因多种药物的可及性、耐药性的出现以及缺乏经过验证的预后和预测生物标志物而变得复杂。本综述探讨了血管生成靶向疗法在mCRC患者二线治疗中的应用。讨论了耐药机制和抗胎盘生长因子药物，并强调了阿柏西普（一种由人血管内皮生长因子受体（VEGFR）-1和VEGFR-2部分组成的重组融合蛋白）的作用。阿柏西普的新型作用机制使其成为在基于奥沙利铂的化疗后进展的mCRC患者以及贝伐单抗治疗后耐药患者中的一种有用的二线药物。